샘플 요청 목록

 카트 문의
시장보고서
상품코드
1402951

세계의 방사성의약품 전임상 CRO 시장 : 성장, 향후 전망, 경쟁 분석(2024-2032년)

Radiopharmaceutical Preclinical CRO Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 115 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

방사성의약품 전임상 CRO 시장은 방사성의약품 분야의 전임상 연구를 촉진하는 데 필수적인 역동적인 부문입니다. 방사성의약품 전임상 CRO 시장은 PET 트레이서 연구의 발전, 종양학 및 신경학 연구 수요 증가, CRO 간 전략적 제휴 등으로 2024-2032년 예측 기간 동안 8.5%의 CAGR을 기록할 것으로 예상됩니다. 치료용 방사성의약품 개발의 도전과제는 원활한 중개연구의 중요성을 강조하고 있습니다. 방사성의약품 유형 및 치료 분야별 세분화는 치료용도로의 전환과 신경학 연구의 중요성 증가를 강조하며 시장 역학에 대한 미묘한 이해를 제공합니다. 지리적 세분화는 세계 트렌드와 전임상 방사성의약품 연구의 미래를 형성하는 데 있어 아시아태평양의 매우 중요한 역할을 강조합니다.

PET 트레이서 연구의 발전

양전자방사선단층촬영(PET) 트레이서 연구의 발전으로 방사성의약품 전임상 CRO 시장이 크게 활성화되고 있습니다. 이를 증명하듯, 코반스(Covance), 찰스 리버 연구소(Charles River Laboratories)와 같은 대형 CRO들은 다양한 전임상시험을 위한 새로운 PET 트레이서 개발에 적극적으로 기여하고 있습니다. 보다 정확한 이미징과 분석이 가능해져 질병 기전과 치료 반응에 대한 더 깊은 이해를 돕습니다.

종양학 연구 수요 확대

종양학 연구에 대한 수요 증가는 방사성의약품 전임상 CRO 시장의 주요 촉진요인이며, Jubilant Biosys와 Selcia와 같은 CRO는 암 분야 전임상 연구가 급증하고 있다는 증거 데이터를 가지고 있습니다. 암 치료 분야는 2024년에 큰 수익을 창출할 뿐만 아니라 2024-2032년 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 보입니다. 이는 암 연구 발전을 지원하고 진단 및 치료 목적의 혁신적인 방사성의약품 연구개발에 기여하는 CRO의 매우 중요한 역할을 뒷받침합니다.

신경학 연구에 대한 관심 증가

신경학 연구에 대한 관심이 높아지면서 방사성의약품 전임상 CRO 시장의 또 다른 촉진요인으로 부상하고 있습니다. 증거 기반 인사이트에 따르면, 파마론(Pharmaron)과 우시 앱텍(WuXi AppTec)과 같은 CRO는 신경학에 초점을 맞춘 전임상 연구에 적극적으로 참여하고 있습니다. 이미징 기술의 발전과 신경 퇴행성 질환에 대한 이해도가 높아짐에 따라 신경계 치료 분야는 예측 기간 동안 큰 수익과 높은 예상 CAGR을 보일 것으로 예상됩니다. 이는 신경과학 연구 지원에서 CRO의 중요한 역할을 강조하며, 신경질환의 진단과 치료에 있어 획기적인 진전을 이룰 수 있는 길을 열어줄 것으로 보입니다.

치료용 방사성의약품 개발의 과제

긍정적인 모멘텀에도 불구하고, 치료용 방사성의약품 개발의 어려움은 여전히 존재하고 있습니다. 전임상 연구 결과를 임상적으로 실행 가능한 치료용 방사성의약품으로 전환하는 데 있어 때때로 장애물이 있다는 증거가 있으며, Eurofins DiscoverX와 Nuvisan을 포함한 CRO들은 전임상에서 임상 개발로의 원활한 전환의 필요성을 강조하며 이러한 과제에 적극적으로 대응하고 있습니다. 적극적으로 대응하고 있습니다. 이러한 저해요인은 장벽을 극복하고 전임상 검증을 거친 방사성의약품의 임상 전환을 촉진하기 위한 공동의 노력과 탄탄한 중개연구 프레임워크의 중요성을 강조합니다.

방사성의약품 유형별 시장 분석 : PET 트레이서가 시장을 장악

방사성의약품 유형별 시장 세분화는 PET 트레이서, SPECT(단광자 방출 컴퓨터 단층 촬영) 트레이서, 치료용 방사성의약품의 역동적인 추세를 보여주며, 2024년에는 PET 트레이서가 시장을 지배하며 가장 높은 수익을 창출할 것으로 예상됩니다, 전체 시장 점유율에 크게 기여하고 있습니다. 그러나 2024년부터 2032년까지 예측 기간 동안 가장 높은 CAGR을 보일 것으로 예상되는 것은 치료용 방사성의약품입니다. 이러한 세분화는 방사성의약품 전임상 연구의 발전과 함께 치료적 용도로의 뚜렷한 전환을 뒷받침합니다.

치료 분야별 시장 분석 : 암 분야가 시장을 독점

치료 영역별 시장 분석은 전임상 연구에서 종양학, 순환기학, 신경학 및 기타 영역의 우위를 강조하고 있으며, 2024년에는 종양학이 암 관련 연구에 대한 관심이 증가함에 따라 가장 높은 매출을 기록할 것으로 예상됩니다. 동시에 신경학은 2024-2032년 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상되며, 이는 신경 질환에 대한 이해와 대처에 대한 관심이 높아진 것을 반영합니다. 이 세분화는 여러 치료 영역에서 전임상시험에서 방사성의약품의 다양한 용도에 대한 인사이트를 제공합니다.

북미는 여전히 세계 선두주자

방사성의약품 전임상 CRO 시장의 지리적 세분화는 세계 트렌드와 지역적 차이를 드러내고 있으며, 2024년에는 북미가 Covance 및 Charles River Laboratories와 같은 CRO가 매출과 시장 점유율 모두에서 선두를 차지하며 중요한 역할을 할 것으로 예상됩니다. 할 것입니다. 그러나 아시아태평양은 신흥 경제국의 연구개발에 대한 집중도가 높아지고 세계 제약사와의 공동연구가 증가함에 따라 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다. 이러한 변화는 시장의 세계 특성과 다양한 연구 환경에 대응하기 위한 지역별 전략의 필요성을 강조하고 있습니다.

예측 기간 동안 심화될 시장 경쟁

경쟁 환경의 특징은 전략적 제휴와 전반적인 시장 전망으로, 2024년 현재 코반스, Charles River Laboratories, Pharmaron과 같은 CRO가 시장을 독점하고 있으며, 이는 종합적인 역량과 전임상 연구에 대한 막대한 기여를 반영하고 있습니다. 2024년부터 2032년까지 이들 CRO는 새로운 시장 역학에 적응하고 세계 방사성의약품 연구 발전에 기여하기 위해 전략적 이니셔티브를 지속하고 새로운 시장 역학에 적응하기 위해 2024-2032년 동안 제약사와의 협력, 서비스 제공 확대, 첨단 기술 투자 등의 전략을 펼칠 것으로 예상됩니다.

본 보고서에서 답변하는 주요 질문

방사성의약품 전임상 CRO 시장의 성장에 영향을 미치는 주요 미시적 및 거시적 환경 요인은 무엇인가?

현재 및 예측 기간 동안 제품 부문 및 지역에 대한 주요 투자 포켓은 무엇인가?

2032년까지의 추정치 및 시장 전망

예측 기간 동안 가장 빠른 CAGR을 차지하는 부문은 무엇인가?

시장 점유율이 높은 부문과 그 이유는 무엇인가?

중저소득 국가는 방사성의약품 전임상 CRO 시장에 투자하고 있는가?

방사성의약품 전임상 CRO 시장에서 가장 큰 지역 시장은 어디인가?

아시아태평양, 라틴아메리카, 중동 및 아프리카 등 신흥 시장의 시장 동향과 역학은?

방사성의약품 전임상 CRO 시장의 성장을 촉진하는 주요 동향은?

세계 방사성의약품 전임상 CRO 시장에서 입지를 강화하기 위한 주요 경쟁사 및 전략은?

목차

제1장 서문

  • 보고서 내용
  • 시장 세분화
  • 조사 방법

제2장 주요 요약

제3장 방사성의약품 전임상 CRO 시장 : 경쟁 분석

  • 주요 벤더의 시장에서의 포지셔닝
  • 벤더가 채용하는 전략
  • 주요 산업 전략
  • 계층 분석 : 2023년 vs 2031년

제4장 방사성의약품 전임상 CRO 시장 : 거시적 분석과 시장 역학

  • 서론
  • 세계의 방사성의약품 전임상 CRO 시장 가치, 2021-2031년
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 성장 촉진요인과 억제요인의 영향 분석
  • See-Saw 분석
  • Porter's Five Forces 모델
    • 공급 기업의 힘
    • 구매자의 능력
    • 대체품의 위협
    • 신규 참여업체의 위협
    • 경쟁 기업 간의 경쟁 관계
  • PESTEL 분석
    • 정치적 상황
    • 경제 상황
    • 기술 상황
    • 법적 상황
    • 사회적 상황

제5장 방사성의약품 전임상 CRO 시장 : 서비스 유형별, 2022-2032년

  • 시장 개요
  • 성장·매출 분석 : 2023년 vs 2031년
  • 시장 세분화
    • 안전성 평가
    • 생체 분석 검사
    • 용량 제제
    • 약사 관련 서포트

제6장 방사성의약품 전임상 CRO 시장 : 최종 이용 산업별, 2022-2032년

  • 시장 개요
  • 성장·매출 분석 : 2023년 vs 2031년
  • 시장 세분화
    • 제약 기업
    • 바이오테크놀러지 기업
    • 학술조사기관
    • 정부기관

제7장 방사성의약품 전임상 CRO 시장 : 방사성의약품 유형별, 2022-2032년

  • 시장 개요
  • 성장·매출 분석 : 2023년 vs 2031년
  • 시장 세분화
    • PET 트레이서
    • SPECT 트레이서
    • 치료용 방사성의약품

제8장 방사성의약품 전임상 CRO 시장 : 치료 분야별, 2022-2032년

  • 시장 개요
  • 성장·매출 분석 : 2023년 vs 2031년
  • 시장 세분화
    • 종양학
    • 심장병학
    • 신경내과
    • 기타

제9장 방사성의약품 전임상 CRO 시장 : 조직 규모별, 2022-2032년

  • 시장 개요
  • 성장·매출 분석 : 2023년 vs 2031년
  • 시장 세분화
    • 중소기업(SME)
    • 대형 제약회사

제10장 북미의 방사성의약품 전임상 CRO 시장, 2022-2032년

  • 시장 개요
  • 방사성의약품 전임상 CRO 시장 : 서비스 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 최종 이용 산업별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 방사성의약품 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 치료 분야별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 조직 규모별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 지역별, 2022-2032년
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제11장 영국 및 유럽연합의 방사성의약품 전임상 CRO 시장, 2022-2032년

  • 시장 개요
  • 방사성의약품 전임상 CRO 시장 : 서비스 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 최종 이용 산업별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 방사성의약품 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 치료 분야별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 조직 규모별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 지역별, 2022-2032년
    • 영국 및 유럽연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 영국 및 유럽연합

제12장 아시아태평양의 방사성의약품 전임상 CRO 시장, 2022-2032년

  • 시장 개요
  • 방사성의약품 전임상 CRO 시장 : 서비스 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 최종 이용 산업별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 방사성의약품 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 치료 분야별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 조직 규모별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 지역별, 2022-2032년
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제13장 라틴아메리카의 방사성의약품 전임상 CRO 시장, 2022-2032년

  • 시장 개요
  • 방사성의약품 전임상 CRO 시장 : 서비스 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 최종 이용 산업별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 방사성의약품 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 치료 분야별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 조직 규모별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 지역별, 2022-2032년
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제14장 중동 및 아프리카의 방사성의약품 전임상 CRO 시장, 2022-2032년

  • 시장 개요
  • 방사성의약품 전임상 CRO 시장 : 서비스 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 최종 이용 산업별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 방사성의약품 유형별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 치료 분야별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 조직 규모별, 2022-2032년
  • 방사성의약품 전임상 CRO 시장 : 지역별, 2022-2032년
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제15장 기업 개요

  • Charles River Laboratories International Inc.
  • Pharmaron Beijing Co. Ltd.
  • Bioscan Inc.
  • Invicro(Konica Minolta)
  • PerkinElmer Inc.
  • Siemens Healthineers
  • IBA Radiopharma Solutions
  • Covance Inc.(Labcorp Drug Development)
  • NorthStar Medical Radioisotopes LLC
  • PAREXEL International Corporation
  • Eckert & Ziegler
  • Jubilant Radiopharma
  • Cardinal Health Inc.
  • Curium Pharma
  • ImaginAb Inc.
  • 기타 주요 기업
ksm 24.01.15

The radiopharmaceutical preclinical CRO (Contract Research Organization) market is a dynamic sector, integral to advancing preclinical research in the field of radiopharmaceuticals. The radiopharmaceutical preclinical CRO market is expected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2032, driven by advancements in PET tracers research, the growing demand for oncology and neurology studies, and strategic collaborations among CROs. Challenges in therapeutic radiopharmaceutical development highlight the importance of seamless translational research. The segmentation by radiopharmaceutical type and therapeutic area provides a nuanced understanding of market dynamics, emphasizing the shift towards therapeutic applications and the rising significance of neurology research. The geographic segmentation underscores global trends and the pivotal role of regions like Asia-Pacific in shaping the future of preclinical radiopharmaceutical research.

Advancements in PET Tracers Research

The radiopharmaceutical preclinical CRO market experiences a significant boost from the ongoing advancements in PET (Positron Emission Tomography) tracers research. Evidence suggests that leading CROs, such as Covance and Charles River Laboratories, have actively contributed to the development of novel PET tracers for various preclinical studies. The increased sensitivity and precision offered by PET tracers enable more accurate imaging and analysis in preclinical trials, facilitating a deeper understanding of disease mechanisms and therapeutic responses.

Growing Demand for Oncology Research

The growing demand for oncology research acts as a major driver for the radiopharmaceutical preclinical CRO market. Evidential data indicates that CROs, including Jubilant Biosys and Selcia, have witnessed a surge in preclinical studies focused on oncology. The oncology therapeutic area not only commands substantial revenue in 2024 but also exhibits the highest expected CAGR during the forecast period from 2024 to 2032. This driver underscores the pivotal role of CROs in supporting advancements in cancer research, contributing to the development of innovative radiopharmaceuticals for diagnostic and therapeutic purposes.

Rising Interest in Neurology Studies

The rising interest in neurology studies emerges as another driver for the radiopharmaceutical preclinical CRO market. Evidence-based insights reveal that CROs, such as Pharmaron and WuXi AppTec, are actively engaged in preclinical research focusing on neurology. With advancements in imaging techniques and a growing understanding of neurodegenerative disorders, the neurology therapeutic area exhibits both substantial revenue and a high expected CAGR during the forecast period. This driver highlights the crucial role of CROs in supporting neuroscience research, paving the way for potential breakthroughs in the diagnosis and treatment of neurological conditions.

Challenges in Therapeutic Radiopharmaceutical Development

Despite the positive momentum, challenges in therapeutic radiopharmaceutical development pose a notable restraint. Evidence suggests occasional hurdles in the translation of preclinical findings to clinically viable therapeutic radiopharmaceuticals. CROs, including Eurofins DiscoverX and Nuvisan, actively address these challenges, emphasizing the need for seamless transitions from preclinical to clinical development. This restraint underscores the importance of collaborative efforts and a robust translational research framework to overcome barriers and expedite the clinical translation of preclinically validated radiopharmaceuticals.

Market Analysis by Radiopharmaceutical Type: PET Tracers Dominate the Market

Market segmentation by radiopharmaceutical type reveals dynamic trends in PET tracers, SPECT (Single Photon Emission Computed Tomography) tracers, and therapeutic radiopharmaceuticals. In 2024, PET tracers dominated the market, with the highest revenue and a significant contribution to the overall market share. However, the highest expected CAGR during the forecast period from 2024 to 2032 is in therapeutic radiopharmaceuticals. This segmentation underscores the evolving landscape of radiopharmaceutical preclinical research, with a notable shift toward therapeutic applications.

Market Analysis by Therapeutic Area: Oncology Segment Dominates the Market

The market segmentation by therapeutic area highlights the prominence of oncology, cardiology, neurology, and other areas in preclinical research. In 2024, oncology commands the highest revenue, driven by the increasing focus on cancer-related studies. Simultaneously, neurology emerges with the highest expected CAGR during the forecast period from 2024 to 2032, reflecting a growing emphasis on understanding and addressing neurological disorders. This segmentation provides insights into the diverse applications of radiopharmaceuticals in preclinical studies across multiple therapeutic areas.

North America Remains the Global Leader

The geographic segmentation of the radiopharmaceutical preclinical CRO market unveils global trends and regional variances. In 2024, North America led in terms of both revenue and market share, with CROs like Covance and Charles River Laboratories playing a significant role. However, Asia-Pacific is expected to exhibit the highest CAGR during the forecast period, driven by factors such as a growing focus on research and development in emerging economies and increasing collaborations with global pharmaceutical companies. This shift highlights the global nature of the market and the need for region-specific strategies to cater to diverse research landscapes.

Market Competition to Intensify during the Forecast Period

The competitive landscape of the radiopharmaceutical preclinical CRO market is characterized by strategic collaborations and a holistic market outlook. In 2024, CROs such as Covance, Charles River Laboratories, and Pharmaron dominated the market, reflecting their comprehensive capabilities and significant contributions to preclinical research. Strategies encompass collaborative ventures with pharmaceutical companies, expansion of service offerings, and investments in cutting-edge technologies. Looking ahead to the period from 2024 to 2032, these CROs are expected to continue their strategic initiatives, adapting to emerging market dynamics and contributing to the advancement of radiopharmaceutical research on a global scale.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofRadiopharmaceutical Preclinical CRO market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Radiopharmaceutical Preclinical CRO market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Service Type

    • Safety Assessment
    • Bioanalytical Testing
    • Dose Formulation
    • Regulatory Affairs Support

End-Use Industry

    • Pharmaceutical Companies
    • Biotechnology Firms
    • Academic Research Institutions
    • Government Organizations

Radiopharmaceutical Type

    • PET Tracers
    • SPECT Tracers
    • Therapeutic Radiopharmaceuticals

Therapeutic Area

    • Oncology
    • Cardiology
    • Neurology
    • Others

Organization Size

    • Small and Medium Enterprises (SMEs)
    • Large Pharmaceutical Corporations

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Radiopharmaceutical Preclinical CRO market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Radiopharmaceutical Preclinical CRO market?

Which is the largest regional market for Radiopharmaceutical Preclinical CRO market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Radiopharmaceutical Preclinical CRO market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Radiopharmaceutical Preclinical CRO market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Radiopharmaceutical Preclinical CRO Market
  • 2.2. Global Radiopharmaceutical Preclinical CRO Market, By Service Type, 2023 (US$ Million)
  • 2.3. Global Radiopharmaceutical Preclinical CRO Market, By End-Use Industry, 2023 (US$ Million)
  • 2.4. Global Radiopharmaceutical Preclinical CRO Market, By Radiopharmaceutical Type, 2023 (US$ Million)
  • 2.5. Global Radiopharmaceutical Preclinical CRO Market, By Therapeutic Area, 2023 (US$ Million)
  • 2.6. Global Radiopharmaceutical Preclinical CRO Market, By Organization Size, 2023 (US$ Million)
  • 2.7. Global Radiopharmaceutical Preclinical CRO Market, By Geography, 2023 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2023

3. Radiopharmaceutical Preclinical CRO Market: Competitive Analysis

  • 3.1. Market Positioning of Key Radiopharmaceutical Preclinical CRO Market Vendors
  • 3.2. Strategies Adopted by Radiopharmaceutical Preclinical CRO Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2031

4. Radiopharmaceutical Preclinical CRO Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Radiopharmaceutical Preclinical CRO Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Safety Assessment
    • 5.3.2. Bioanalytical Testing
    • 5.3.3. Dose Formulation
    • 5.3.4. Regulatory Affairs Support

6. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Pharmaceutical Companies
    • 6.3.2. Biotechnology Firms
    • 6.3.3. Academic Research Institutions
    • 6.3.4. Government Organizations

7. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. PET Tracers
    • 7.3.2. SPECT Tracers
    • 7.3.3. Therapeutic Radiopharmaceuticals

8. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Oncology
    • 8.3.2. Cardiology
    • 8.3.3. Neurology
    • 8.3.4. Others

9. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2023 Versus 2031
  • 9.3. Market Segmentation
    • 9.3.1. Small and Medium Enterprises (SMEs)
    • 9.3.2. Large Pharmaceutical Corporations

10. North America Radiopharmaceutical Preclinical CRO Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
  • 10.3. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
  • 10.4. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
  • 10.5. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
  • 10.6. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
  • 10.7.Radiopharmaceutical Preclinical CRO Market: By Region, 2022-2032, USD (Million)
    • 10.7.1.North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 10.7.1.1.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 10.7.1.1.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 10.7.1.1.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 10.7.1.1.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 10.7.1.2.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 10.7.1.2.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 10.7.1.2.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 10.7.1.2.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 10.7.1.3.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 10.7.1.3.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 10.7.1.3.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 10.7.1.3.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)

11. UK and European Union Radiopharmaceutical Preclinical CRO Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
  • 11.3. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
  • 11.4. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
  • 11.5. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
  • 11.6. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
  • 11.7.Radiopharmaceutical Preclinical CRO Market: By Region, 2022-2032, USD (Million)
    • 11.7.1.UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 11.7.1.1.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 11.7.1.1.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 11.7.1.1.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 11.7.1.1.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 11.7.1.2.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 11.7.1.2.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 11.7.1.2.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 11.7.1.2.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 11.7.1.3.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 11.7.1.3.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 11.7.1.3.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 11.7.1.3.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 11.7.1.4.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 11.7.1.4.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 11.7.1.4.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 11.7.1.4.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 11.7.1.5.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 11.7.1.5.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 11.7.1.5.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 11.7.1.5.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 11.7.1.6.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 11.7.1.6.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 11.7.1.6.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 11.7.1.6.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)

12. Asia Pacific Radiopharmaceutical Preclinical CRO Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
  • 12.3. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
  • 12.4. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
  • 12.5. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
  • 12.6. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
  • 12.7.Radiopharmaceutical Preclinical CRO Market: By Region, 2022-2032, USD (Million)
    • 12.7.1.Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 12.7.1.1.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 12.7.1.1.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 12.7.1.1.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 12.7.1.1.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 12.7.1.2.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 12.7.1.2.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 12.7.1.2.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 12.7.1.2.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 12.7.1.3.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 12.7.1.3.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 12.7.1.3.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 12.7.1.3.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 12.7.1.4.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 12.7.1.4.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 12.7.1.4.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 12.7.1.4.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 12.7.1.5.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 12.7.1.5.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 12.7.1.5.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 12.7.1.5.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 12.7.1.6.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 12.7.1.6.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 12.7.1.6.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 12.7.1.6.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)

13. Latin America Radiopharmaceutical Preclinical CRO Market, 2022-2032, USD (Million)

  • 13.1. Market Overview
  • 13.2. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
  • 13.3. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
  • 13.4. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
  • 13.5. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
  • 13.6. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
  • 13.7.Radiopharmaceutical Preclinical CRO Market: By Region, 2022-2032, USD (Million)
    • 13.7.1.Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 13.7.1.1.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 13.7.1.1.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 13.7.1.1.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 13.7.1.1.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 13.7.1.2.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 13.7.1.2.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 13.7.1.2.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 13.7.1.2.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 13.7.1.3.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 13.7.1.3.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 13.7.1.3.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 13.7.1.3.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)

14. Middle East and Africa Radiopharmaceutical Preclinical CRO Market, 2022-2032, USD (Million)

  • 14.1. Market Overview
  • 14.2. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
  • 14.3. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
  • 14.4. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
  • 14.5. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
  • 14.6. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
  • 14.7.Radiopharmaceutical Preclinical CRO Market: By Region, 2022-2032, USD (Million)
    • 14.7.1.Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 14.7.1.1.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 14.7.1.1.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 14.7.1.1.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 14.7.1.1.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 14.7.1.2.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 14.7.1.2.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 14.7.1.2.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 14.7.1.2.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Radiopharmaceutical Preclinical CRO Market: By Service Type, 2022-2032, USD (Million)
        • 14.7.1.3.2. Radiopharmaceutical Preclinical CRO Market: By End-Use Industry, 2022-2032, USD (Million)
        • 14.7.1.3.3. Radiopharmaceutical Preclinical CRO Market: By Radiopharmaceutical Type, 2022-2032, USD (Million)
        • 14.7.1.3.4. Radiopharmaceutical Preclinical CRO Market: By Therapeutic Area, 2022-2032, USD (Million)
        • 14.7.1.3.5. Radiopharmaceutical Preclinical CRO Market: By Organization Size, 2022-2032, USD (Million)

15. Company Profile

  • 15.1. Charles River Laboratories International, Inc.
    • 15.1.1. Company Overview
    • 15.1.2. Financial Performance
    • 15.1.3. Product Portfolio
    • 15.1.4. Strategic Initiatives
  • 15.2. Pharmaron Beijing Co., Ltd.
    • 15.2.1. Company Overview
    • 15.2.2. Financial Performance
    • 15.2.3. Product Portfolio
    • 15.2.4. Strategic Initiatives
  • 15.3. Bioscan, Inc.
    • 15.3.1. Company Overview
    • 15.3.2. Financial Performance
    • 15.3.3. Product Portfolio
    • 15.3.4. Strategic Initiatives
  • 15.4. Invicro (Konica Minolta)
    • 15.4.1. Company Overview
    • 15.4.2. Financial Performance
    • 15.4.3. Product Portfolio
    • 15.4.4. Strategic Initiatives
  • 15.5. PerkinElmer, Inc.
    • 15.5.1. Company Overview
    • 15.5.2. Financial Performance
    • 15.5.3. Product Portfolio
    • 15.5.4. Strategic Initiatives
  • 15.6. Siemens Healthineers
    • 15.6.1. Company Overview
    • 15.6.2. Financial Performance
    • 15.6.3. Product Portfolio
    • 15.6.4. Strategic Initiatives
  • 15.7. IBA Radiopharma Solutions
    • 15.7.1. Company Overview
    • 15.7.2. Financial Performance
    • 15.7.3. Product Portfolio
    • 15.7.4. Strategic Initiatives
  • 15.8. Covance, Inc. (Labcorp Drug Development)
    • 15.8.1. Company Overview
    • 15.8.2. Financial Performance
    • 15.8.3. Product Portfolio
    • 15.8.4. Strategic Initiatives
  • 15.9. NorthStar Medical Radioisotopes, LLC
    • 15.9.1. Company Overview
    • 15.9.2. Financial Performance
    • 15.9.3. Product Portfolio
    • 15.9.4. Strategic Initiatives
  • 15.10. PAREXEL International Corporation
    • 15.10.1. Company Overview
    • 15.10.2. Financial Performance
    • 15.10.3. Product Portfolio
    • 15.10.4. Strategic Initiatives
  • 15.11. Eckert & Ziegler
    • 15.11.1. Company Overview
    • 15.11.2. Financial Performance
    • 15.11.3. Product Portfolio
    • 15.11.4. Strategic Initiatives
  • 15.12. Jubilant Radiopharma
    • 15.12.1. Company Overview
    • 15.12.2. Financial Performance
    • 15.12.3. Product Portfolio
    • 15.12.4. Strategic Initiatives
  • 15.13. Cardinal Health, Inc.
    • 15.13.1. Company Overview
    • 15.13.2. Financial Performance
    • 15.13.3. Product Portfolio
    • 15.13.4. Strategic Initiatives
  • 15.14. Curium Pharma
    • 15.14.1. Company Overview
    • 15.14.2. Financial Performance
    • 15.14.3. Product Portfolio
    • 15.14.4. Strategic Initiatives
  • 15.15. ImaginAb, Inc.
    • 15.15.1. Company Overview
    • 15.15.2. Financial Performance
    • 15.15.3. Product Portfolio
    • 15.15.4. Strategic Initiatives
  • 15.16. Other Notable Players
    • 15.16.1. Company Overview
    • 15.16.2. Financial Performance
    • 15.16.3. Product Portfolio
    • 15.16.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제